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Abstract
Purpose Therapy with [177Lu-DOTA,Tyr3]octreotate is effective in patients with grade I/II metastasized and/or inoperable
bronchial neuroendocrine tumour (NET) or gastroenteropancreatic NET (GEP-NET). In this study, we investigated the efficacy
and safety of salvage treatment with [177Lu-DOTA,Tyr3]octreotate.
Methods Patients with progressive bronchial NET or GEP-NET were selected for re-(re)treatment if they had benefited from
initial peptide receptor radionuclide therapy (I-PRRT) with a minimal progression-free survival (PFS) of 18 months. Patients
received an additional cumulative dose of 14.8 GBq of [177Lu-DOTA,Tyr3]octreotate over two cycles per retreatment with PRRT
(R-PRRT) or re-retreatment with PRRT (RR-PRRT).
Results The safety and efficacy analyses included 181 patients and 168 patients, respectively, with bronchial NETor GEP-NET.
Overall median follow-up was 88.6 months (95% CI 79.0–98.2). Median cumulative doses were 44.7 GBq (range 26.3–
46.4 GBq) during R-PRRT (168 patients) and 59.7 GBq (range 55.2–≤60.5 GBq) during RR-PRRT (13 patients). Objective
response and stable disease, as best response, were observed in 26 patients (15.5%) and 100 patients (59.5%) following R-PRRT,
and in 5 patients (38.5%) and 7 patients (53.8%) following RR-PRRT, respectively. Median PFS was 14.6 months (95%CI 12.4–
16.9) following R-PRRTand 14.2months (95%CI 9.8–18.5) following RR-PRRT. Combined overall survival (OS) after I-PRRT
plus R-PRRT and RR-PRRT was 80.8 months (95% CI 66.0–95.6). Grade III/IV bone marrow toxicity occurred in 6.6% and
7.7% of patients after R-PRRTand RR-PRRT, respectively. Salvage therapy resulted in a significantly longer OS in patients with
bronchial NET, GEP-NET and midgut NET than in a nonrandomized control group. The total incidence of acute myeloid
leukaemia (AML) and myelodysplastic syndrome (MDS) was 2.2%. No PRRT-related grade III/IV nephrotoxicity was observed.
Conclusion A cumulative dose of up to 60.5 GBq salvage PRRT with [177Lu-DOTA,Tyr3]octreotate is safe and effective in
patients with progressive disease (relapse-PD) following I-PRRT with [177Lu-DOTA,Tyr3]octreotate. Safety appears similar to
that of I-PRRT as no higher incidence of AML or MDS was observed. No grade III/IV renal toxicity occurred after retreatment.
Keywords PRRT . Salvage . Efficacy . Safety . Gastroenteropancreatic . Neuroendocrine
Introduction
Well-differentiated neuroendocrine tumours (NETs) are known
to display a relatively indolent behaviour. Their current incidence
is about 7 per 100,000 persons. There has been a gradual increase
in their incidence over recent years [1]. Somatostatin analogues
and the mammalian target of rapamycin (mTOR) inhibitor,
everolimus, prolong progression-free survival (PFS) in patients
with inoperable, advanced (metastatic) gastroenteropancreatic
NET (GEP-NET), and sunitinib is approved for the treatment
of advanced (metastatic) pancreaticNET [2–5]. However, recent-
ly the NETTER-1 study has demonstrated a superior outcome in
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terms of longer PFS (28.4 vs. 8.5 months) and overall survival
(OS, ‘not reached’ after 42.0 months vs. 27.4 months) after pep-
tide receptor radionuclide therapy (PRRT) with [177Lu-
DOTA,Tyr3]octreotate plus 30mgoctreotide LARevery 4weeks
comparedwith high-dose octreotide LAR (60mg every 4weeks)
in patients with advanced midgut NET, all previously treated
with regular doses of octreotide LAR (20–30 mg every 4 weeks)
[6, 7]. The US Food and Drug Administration (FDA) has there-
fore approvedLutathera® ([177Lu-DOTA,Tyr3]octreotate) for the
treatment of somatostatin receptor-positive GEP-NET, including
foregut, midgut and hindgut NETs, in adults. The European
Medicines Agency (EMA) and the European Commission
(EC) have also approved Lutathera® for the treatment of
unresectable or metastatic, progressive, well-differentiated (grade
I/II), somatostatin receptor-positive GEP-NET in adults.
For PRRT, high expression of somatostatin receptor
subtypes on the surface of NET cells is required [8]. With
respect to treatment outcome, initial PRRT (I-PRRT) with
[177Lu-DOTA,Tyr3]octreotate has demonstrated objective
radiological responses (ORR) in 29–39% and stabilization
in 27–43% of patients with bronchial NET or GEP-NET
[8–10]. The overall tolerability of PRRT is good; short-
term and long-term side effects have been shown in the
bone marrow and kidneys, but are mostly mild and revers-
ible. There is a risk of approximately 2% for developing
myeloproliferative disorders, including myelodysplastic
syndrome (MDS) and acute myeloid leukaemia (AML)
[8, 9, 11]. Eventually, most patients will demonstrate pro-
gressive disease (PD) after I-PRRT with limited treatment
options left, particularly those with midgut NET.
Interestingly, previous studies have indicated that salvage
PRRT is feasible. Current data on salvage PRRT are mostly
derived from studies with small patient cohorts and limited
follow-up times. In some studies, different radioligands or
their combinations have been used for I-PRRT and
retreatment with PRRT (R-PRRT) [12–17].
Here we present the results in the largest cohort of patients
from a single institution who underwent I-PRRT, R-PRRTand
re-retreatment with PRRT (RR-PRRT) with only [177Lu-
DOTA,Tyr3]octreotate and with the longest follow-up.
Control groups consisting of patients not undergoing salvage
therapy, but in principle qualifying for it, were established for
comparison of median PFS after I-PRRT and OS in patients
with bronchial NETor GEP-NET, and in the largest subgroups
with midgut or pancreatic NET.
Materials and methods
Retreatment group selection
Dutch patients with advanced bronchial NET or GEP-
NET who underwent R-PRRT or RR-PRRT between
October 2003 and October 2015 were selected. Follow-
up data were analysed until 1 January 2017. All included
patients experienced PD (relapse-PD) after a period of
disease control fo l lowing I-PRRT with [177Lu-
DOTA,Tyr3]octreotate. Disease control was defined as
an objective response or stable disease (SD) according
to the Response Evaluation Criteria in Solid Tumours
1.1 (RECIST 1.1). PD was based on CT or MRI or pro-
gression on [111In-DTPA0]octreotide scintigraphy
(OctreoScan®). However, in a few patients salvage
PRRT was started based on clinical deterioration without
the requirement of qualifying for objective radiological
progression. Relapse-PD is defined as the moment of PD
before the start of R-PRRT and/or RR-PRRT, irrespective
of known or objective PD before the start of I-PRRT. The
same inclusion criteria as previously described for I-PRRT
were applied for R-PRRT and RR-PRRT [8]. In brief, a
Krenning tumour uptake score of at least grade II on the
OctreoScan® and within the qualifying renal and haema-
tological limits were required. In addition, only those pa-
tients with a PFS of ≥18.0 months from the first admin-
istration of I-PRRT were considered eligible for R-PRRT,
and those with a PFS ≥14.0 months after R-PRRT for RR-
PRRT.
Nonrandomized control group selection
For estimation of a potential increase in OS, three
nonrandomized but matched control groups were obtained,
consisting of patients with bronchial and GEPNET, midgut
NET or pancreatic NET. Group 1: bronchial and GEP-NET,
Group 2: midgut NET, Group 3: pancreatic NET. These
patients were treated and selected in our hospital and received
21.8–30.6 GBq [177Lu-DOTA,Tyr3]octreotate I-PRRT during
the same study period and in principle could qualify for
R-PRRT on the basis of the criteria described above. The
reasons for control patients (99 patients) finally not receiving
salvage PRRT were: insufficient uptake on OctreoScan® in
progressive or newly developed lesions (2 patients); failure to
meet renal and/or haematological inclusion parameters
(25 patients); worsening of clinical condition (11 patients);
receiving other local or systemic treatments (14 patients), lost
to follow-up at the time of relapse-PD (9 patients); death
(7 patients); SD after I-PRRT not considered by the treating
investigator as favourable despite PFS ≥18.0 months
(8 patients); wait-and-see strategy followed upon relapse-PD
(2 patients); and development of a secondary primary tumour
which required medical treatment (3 patients). In the remaining
18 control patients, it was unclear why R-PRRT was not
considered. The flow chart presented in Fig. 1 shows the
selection of the retreatment and nonrandomized control group,
Fig. 1; the control group in this flow-chart is not divided in
several groups, including the reasons for exclusion from
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analysis. Patients treated with 26.3– ≤60.5 GBq during
R-PRRT or RR-PRRT were included in the safety analysis.
Subgroups of patients with midgut NET or pancreatic NET
were also separately analysed for efficacy.
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Methods
[DOTA,Tyr3]octreotate was obtained from BioSynthema.
[177Lu-DOTA,Tyr3]octreotate was locally prepared as previ-
ously described [18]. To prevent nausea patients received a
bolus of 3 mg granisetron intravenously. For kidney protec-
tion, an amino acid solution (2.5% arginine and 2.5% lysine in
1 L 0.225%NaCl) was infused over 4 h starting 30 min before
administration of the radiopharmaceutical. The radiopharma-
ceutical itself was coadministered over 30 min via a separate
infusion system. The administered dose per cycle was
7.4 GBq (or 3.7 GBq in patients with previous dose-
modifying toxicity) with an intended cumulative dose of
29.6 GBq. No personalized dosimetry was applied for the
salvage therapy. For R-PRRT and RR-PRRT the intended cu-
mulative doses were 44.4 GBq and 59.2 GBq, respectively.
The interval between treatments was 6 to 10 weeks.
Routine blood analysis for haematology, and liver and kid-
ney function was performed 4–6 weeks after each cycle.
During follow-up, CT or MRI was done at 6 weeks, 3 months
and 6 months after the last treatment. Disease status was then
evaluated biannually. Case report forms were completed at
every hospitalization for treatment and follow-up visit.
Safety was defined using the Common Terminology Criteria
for Adverse Events (CTCAE), version 3.0.
This prospectively designed study with a retrospective
analysis was approved by the medical ethics committee of
our hospital and all patients gave written informed consent
to their participation.
Statistics
The correlations both between tumour response according
to RECIST 1.1 after I-PRRT and response after R-PRRT
and between PFS after I-PRRT and PFS after R-PRRT
were tested using Spearman’s correlation coefficient.
Medians and 95% confidence intervals (CI) for PFS and
OS were estimated by the Kaplan-Meier method. Survival
curves were compared using the log-rank test. Median
follow-up time and median OS were calculated from the
date of first administration of I-PRRT, and PFS from the
date of first administration of I-PRRT, R-PRRT and RR-
PRRT. Possible associations between changes in uptake
on the OctreoScan® (Krenning score on baseline I-
PRRT vs. the score on baseline R-PRRT OctreoScan®)
and tumour response after R-PRRT were analysed using
the chi-squared test. Groups were compared using
Fisher’s exact test. The disease control rate (DCR) was
defined as the proportion of patients who achieved a com-
plete response (CR), partial response (PR) or SD. P values
less than 0.05 were considered to indicate significant dif-
ferences. Ranges are minimum and maximum values.
Results
Baseline characteristics of patients who received I-PRRT, R-
PRRT and RR-PRRT are shown in Table 1. Comparison of
baseline parameters before I-PRRT and R-PRRT showed
higher involvement of liver and/or bone metastases at the
start of R-PRRT, reflecting progression of the disease over
time. In total, seven patients had undergone debulking sur-
gery after I-PRRT without disease progression at the time.
During I-PRRT the retreatment and control patients received
median cumulative doses of 29.9 GBq (range 18.6–
30.7 GBq) and 29.8 GBq (range 21.8–30.6 GBq), respec-
tively. Of 168 patients who underwent R-PRRT, 153 re-
ceived the intended additional dose, and all patients who
underwent RR-PRRT received the intended dose. Patients
received a median cumulative administered dose of
14.9 GBq (3.7–16.2 GBq) and 15.0 GBq (14.7–15.3 GBq),
resulting in total median cumulative administered doses of
44.7 GBq (26.3–46.4 GBq) after R-PRRT and 59.7 GBq
(55.2–60.5 GBq) after RR-PRRT. The main reasons for not
completing the intended number of cycles were persistent
myelotoxicity and clinical deterioration (Table 2). From the
start of I-PRRT, the overall median follow-up time was
88.6 months (95% CI 79.0–98.2 months), including median
follow-up times of 30.4 months (95%CI 22.5–38.4 months)
and 34.5 months (95% CI 16.5–52.5 months) from the start
of R-PRRT and RR-PRRT, respectively.
The efficacy of R-PRRTwas evaluated in 168 patients and
of RR-PRRT in 13 patients with bronchial NETor GEP-NET.
Radiological tumour responses at 3 months and the best re-
sponses after the last treatment cycle are shown in Table 3. R-
PRRT resulted in an ORR of 15.5% and SD of 59.5%. A total
of 33 patients (19.6%) had objective disease progression as
best response after R-PRRT, and of these 54.5% had a PR and
45.5% SD as best response after I-PRRT. Five patients (3.0%)
died before the intended cumulative dose of 14.8 GBq was
given. Three patients (1.8%) showed clinical deterioration and
were considered as having PD during therapy as well. Of 13
RR-PRRT patients, 5 (38.5%) achieved an ORR and 7
(53.8%) achieved SD, and 1 (7.7%) had PD. In the 167 pa-
tients in the retreatment group, radiological tumour responses
to R-PRRT and to I-PRRTwere significantly correlated (rS =
0.259, p < 0.01; data not shown). Figure 2 shows a patient
with metastasized well-differentiated pancreatic NET achiev-
ing a PR after both I-PRRT and R-PRRT.
Irrespective of the tumour response after I-PRRT, after R-
PRRT the median PFS was 14.6 months (95% CI 12.4–
16.9 months) and after RR-PRRT was 14.2 months (95% CI
9.8–18.5 months). However, patients who had SD and PR
after R-PRRT (75%) had a median PFS of 19.4 months
(95% CI 17.2–21.5 months). Seven out of nine patients
(78%) with WHO tumour grade III (Ki-67 index 20–30%)
responded to R-PRRT (six patients with SD and one with
Eur J Nucl Med Mol Imaging
Table 1 Baseline characteristics of patients with bronchial NET or GEP-NET prior to I-PRRT, R-PRRT and RR-PRRT with [177Lu-
DOTA,Tyr3]octreotate
Characteristic Before I-PRRT (n = 168) Before R-PRRT (n = 168) Before RR-PRRT (n = 13) p valuea
Male, n (%) 95 (56.5) 95 (56.5) 9 (69.2)
Age (years), median (range) 59 (32–78) 63 (35–80) 64 (46–78)
Tumour type, n (%)
Bronchial NET 13 (7.7) 13 (7.7) 2 (15.4)
Pancreatic NET 53 (31.5) 53 (31.5) 4 (30.8)
Midgut NET 54 (32.1) 54 (32.1) 2 (15.4)
Baseline progression, n (%)
According RECIST 1.1
Yes 98 (58.3) 152 (90.5) 11 (84.6) <0.01
No 22 (13.1) 2 (1.2) 1 (7.7)
Unknown 48 (28.6) – –
On OctreoScan®
Yes – 13 (7.7) 1 (7.7)
Clinical symptoms
Yes – 1 (0.6) 0 (0.0)
Prior treatment, n (%)
Surgery
Yes 71 (42.3) 7 (4.2)b 0 (0.0)
No 97 (57.7) 161 (95.8) 13 (100)
Chemotherapy
Yes 9 (5.4) – –
No 159 (94.6) – –
Radiotherapy
Yes 12 (7.1) – –
No 155 (92.3) – –
Unknown 1 (0.6) – –
Somatostatin analogues
Yes 98 (58.3) – –
No 70 (41.7) – –
Extent of disease, n (%)c
Limited 23 (13.7) 23 (13.9) 1 (7.7) 1.00
Moderate 122 (72.6) 83 (50.0) 7 (53.8) <0.01
Extensive 23 (13.7) 60 (36.1) 5 (38.5) <0.01
Unknown – 2 (−) 0 (–)
Uptake on OctreoScan®, n (%)
Score 2 9 (5.4) 14 (8.4) 0 (0.0) 0.39
Score 3 93 (55.4) 91 (54.8) 5 (38.5) 0.66
Score 4 66 (39.3) 61 (36.7) 8 (61.5) 0.65
Unknown – 2 (−) 0 (–)
Liver lesions, n (%)
Yes 153 (91.1) 163 (97.0) 13 (100) 0.04
No 15 (8.9) 5 (3.0) 0 (0.0)
Bone lesions, n (%)
Yes 47 (28.0) 74 (44.0) 7 (53.8) <0.01
No 121 (72.0) 94 (56.0) 6 (46.2)
Chromogranin A
>2 × ULN, n (%) 113 (70.2) 117 (70.5) 9 (69.2) 0.48
Serum level (μg/L), median (Q1–Q3) 442 (148–2,027) 462 (117–2,300) 363 (128–1,007)
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PR), and had a median PFS of 13.4 months (95% CI 10.9–
15.8 months). The two patients with PD as best tumour re-
sponse were omitted from this PFS analysis. For the entire
group of 168 patients, PFS after I-PRRT and after R-PRRT
were significantly associated (rS = 0.325, p < 0.01;
Online Resource 1).
Between the baseline I-PRRT and baseline R-PRRT the
OctreoScan® tumour uptake score increased in 27 patients
(16.3%) and decreased in 33 patients (19.9%) (an extended
overview of these findings is given in Online Resource 2).
Only 5 of 33 patients (one patient not evaluable) with PD as
response after R-PRRT had a lower tumour uptake score at the
start of R-PRRT compared with I-PRRT. No relationship was
found between the changes in tumour uptake on OctreoScan®
and tumour response after R-PRRT: χ2 = 3.47 (degrees of
freedom 6, n = 165), p = 0.75.
OS was compared between the matched, nonrandomized
control group of patients with bronchial NET or GEP-NET
after receiving I-PRRT followed by unknown therapies and
the retreatment groups after receiving I-PRRT, R-PRRT, RR-
PRRT and unknown consecutive therapies. The baseline
characteristics of the control and retreatment groups are
shown in Table 4. Both groups were balanced with respect
to baseline progression, prior treatments, extent of disease
and number of patients with increased serum chromogranin
A levels. More patients in the retreatment group had liver
metastases (81.8% of patients in the control group vs. 91.1%
in the retreatment group) and bone lesions (12.1% vs.
28.0%, respectively). A different distribution of tumour up-
take was seen on OctreoScan® (uptake score 3 in 72.7% of
patients in the control group and in 55.4% in the retreatment
group) and tumour grade (WHO grade II in 42.9% of
Table 2 Reasons for not
achieving the intended
cumulative dose of 14.8 GBq
during R-PRRT
Reason Number of patients
(n = 15)
Persistent myelosuppression 4a
Clinical deterioration 4
Objective progressive disease 1
Death after first cycle 3
Development of breast cancer, start of another treatment 1
Stomach ulcer caused by NET, coiling necessary due to severe melaena and
haematemesis
1
Diffuse bone metastases (started with reduced dose) 1
These patients were included in the efficacy analysis
a Thrombocytopenia grade II in two patients, grade III in two patients
Table 1 (continued)
Characteristic Before I-PRRT (n = 168) Before R-PRRT (n = 168) Before RR-PRRT (n = 13) p valuea
Unknown, n (%) 7 (−) 2 (−) 0 (0)
Alkaline phosphatase
>2 × ULN, n (%) 25 (15.5) 35 (21.0) 2 (15.4) 0.20
Serum level (U/L), median (Q1–Q3) 108 (78–159) 110 (78–172) 95 (84–151)
Unknown, n (%) 4 (−) 0 (−) 0 (−)
WHO tumour grade, n (%)d
I 22 (22.7) – –
II 66 (68.0) – –
III 9 (9.3) – –
Unknown 71 (−) – –
Patients of the I-PRRT and R-PRRT groups are the same
ULN upper limit of normal, Q1–Q3 interquartile range
a I-PRRT vs. R-PRRT
b Surgery after I-PRRT and before R-PRRT
cRepresents regional distribution of metastatic spread on OctreoScan® as described previously [22]
dMost patients with an unknown Ki-67 proliferation index were treated before 2007. After 2007 the Ki-67 proliferation index was routinely checked by
MIB-1 staining. Before the start of R-PRRT/RR-PRRT the Ki-67 index was not routinely checked
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patients in the control group and in 68.0% in the retreatment
group). For grading we assumed a similar Ki-67 distribution
in our patient population before and after 2007, the year
measurement of this parameter was introduced in our
institution.
The efficacy of salvage therapy was compared between
168 patients receiving R-PRRT and 99 control patients. OS
and PFS in the various treatment groups in relation to tumour
classification are shown in Table 5. In terms of PFS, the con-
trol group and retreatment group (bronchial NET or GEP-
NET) were well matched. However, the proportions of pa-
tients with midgut NET (n = 63) and pancreatic NET (n =
20) were unevenly distributed in the control group and there-
fore subgroup analyses of patients with midgut NET or pan-
creatic NET were also performed. Baseline characteristics of
the patients with midgut NETor pancreatic NET are shown in
Online Resource 3 and Online Resource 4.
Patients with bronchial NET or GEP-NET treated with sal-
vage PRRT had a significantly longer OS than control patients
(p < 0.01). The combined median OS in patients receiving I-
Table 3 Radiological tumour response evaluation in patients with bronchial NET or GEP-NET
Number
of
patients
Best response NE Clinical
PD
Response at 3 months
follow-up
NE Clinical
PD
Died before
start of
follow-up
CR PR SD PDa PR SD PD
After I-PRRT
Control group 99 0 (0.0) 36 (36.4) 58 (58.6) – 5 (5.1) – – – – – – –
Salvage group 168 1 (0.6) 93 (55.4) 73 (43.5) – 1 (0.6) – – – – – – –
After salvage PRRT
R-PRRT 168 – 26 (15.5) 100 (59.5) 33 (19.6) 1 (0.6) 3 (1.8) 14 (8.3) 111 (66.1) 34 (20.2) 1 (0.6) 3 (1.8) 5 (3.0)
RR-PRRT 13 – 5 (38.5) 7 (53.8) 1 (7.7) – – 2 (15.4) 9 (69.2) 2 (15.4) – – –
The data are presented as number (%) of patients
Patients with PD as best response after I-PRRTwere considered as having treatment failure and were not eligible for subsequent R-PRRT
CR complete response, PR partial response, SD stable disease, PD progressive disease, NE not evaluable
a Salvage patients were thosewith PD after I-PRRTand an initial tumour response of at least SD lasting for at least 18months from the first administration
of the I-PRRT
R-PRRTI-PRRT
cycle 1 cycle 2
a
b
I-PRRT
cycle 3 cycle 4 cycle 1 cycle 2
R-PRRTFig. 2 Planar scintigraphy in a
patient with metastasized well-
differentiated pancreatic NET. a
Images obtained 24 h after
administration of 7.4 GBq of
[177Lu-DOTA0,Tyr3]octreotate
during the initial four cycles (I-
PRRT) and two additional cycles
(R-PRRT) after PD in the first half
of 2015 show high uptake by
somatostatin receptor-positive
tumours. b Course of the tumour
marker chromogranin A (CgA)
during and after treatment with
PRRT
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PRRT, R-PRRT and RR-PRRT was 80.8 months (95% CI
66.0–95.6), and in the control patients was 51.4 months (95%
CI 46.7–56.1 months). In patients with midgut NET, OS was
77.3 months (95% CI 55.0–99.5 months) in the retreatment
Table 4 Baseline characteristics of patients with bronchial NET and GEP-NET in the control group and the retreatment group before any PRRT
Characteristic Control group (n = 99) Retreatment group (n = 168) p value
Male, n (%) 45 (45.5) 95 (56.5)
Age (years), median (range) 64 (37–83) 59 (32–78)
Baseline progression, n (%)a
Yes 46 (46.5) 98 (58.3) 0.08
No 21 (21.2) 22 (13.1)
Unknown 32 (32.3) 48 (28.6)
Prior treatment, n (%)
Surgery
Yes 43 (43.4) 71 (42.3) 0.90
No 56 (56.6) 97 (57.7)
Chemotherapy
Yes 6 (6.1) 9 (5.4) 0.79
No 93 (93.9) 159 (94.6)
Radiotherapy
Yes 3 (3.0) 12 (7.1) 0.18
No 96 (97.0) 155 (92.3)
Unknown – 1 (0.6)
Somatostatin analogues
Yes 54 (54.5) 98 (58.3) 0.61
No 45 (45.5) 70 (41.7)
Extent of disease, n (%)b
Limited 8 (8.1) 23 (13.7) 0.23
Moderate 76 (76.8) 122 (72.6) 0.47
Extensive 15 (15.2) 23 (13.7) 0.06
Uptake on OctreoScan®, n (%)
Score 2 0 (0.0) 9 (5.4) 0.03
Score 3 72 (72.7) 93 (55.4) 0.01
Score 4 27 (27.3) 66 (39.3) 0.06
Liver lesions, n (%)
Yes 81 (81.8) 153 (91.1) 0.03
No 18 (18.2) 15 (8.9)
Bone lesions, n (%)
Yes 12 (12.1) 47 (28.0) <0.01
No 87 (87.9) 121 (72.0)
Chromogranin A
>2 × ULN, n (%) 68 (72.3) 113 (70.2) 0.89
Serum level (μg/L), median (Q1–Q3) 405 (165–2,025) 442 (148–2,027)
Unknown, n (%) 5 (−) 7 (−)
Alkaline phosphatase
>2 × ULN, n (%) 14 (14.1) 25 (15.2) 1.00
Serum level (U/L), median (Q1–Q3) 110 (80–158) 108 (78–159)
Unknown, n (%) 0 (−) 4 (−)
WHO tumour grade, n (%)c
I 15 (53.5) 22 (22.7) 0.71
II 12 (42.9) 66 (68.0) <0.01
III 1 (3.6) 9 (9.3) 0.10
Unknown 71 (−) 71 (−)
Tumour response, n (%)d
CR 0 (0.0) 1 (0.6) 1.00
PR 36 (38.3) 93 (55.7) < 0.01
SD 58 (61.7) 73 (43.7) 0.02
Unknown 5 (−) 1 (−)
ULN upper limit of normal, Q1–Q3 interquartile range, CR complete response, PR partial response, SD stable disease
a Documented progression according RECIST 1.1
b Represents regional distribution of metastatic spread on OctreoScan® as described previously [22]
c Since 2007 the Ki-67 proliferation index was routinely checked by MIB-1 staining. Most patients with an unknown Ki-67 index were treated before
2007
d Tumour response to I-PRRT evaluated according RECIST 1.1
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group and 51.0 months (95% CI 44.6–57.4 months) in the
control patients. In patients with pancreatic NET there was a
trend towards improved OS following salvage PRRT: OS was
93.9 months (95% CI 39.4–148.3 months) in the retreatment
group and 61.5 months (95% CI 49.9–73.2 months) in the
control patients (p not significant; Fig. 3).
Safety was evaluated in 181 R-PRRT patients and 13 RR-
PRRT patients. Grade III/IV subacute haematological toxicity
occurred in 12 R-PRRT patients (6.6%) and in 1 RR-PRRT
patient (7.7%; Table 6). Myeloproliferative toxicity in the R-
PRRT and control patients was not significantly different
(2.2% and 3.5%, respectively). AML was diagnosed in two
patients and MDS in two patients after R-PRRT (Table 7). No
further patients were diagnosed with AML/MDS after RR-
PRRT. No PRRT-related grade III/IV nephrotoxicity was
observed.
Discussion
We report here the safety and efficacy of salvage PRRT in the
largest series of patients receiving [177Lu-DOTA,Tyr3]octreotate
to a cumulative administered dose of up to 60.5 GBq, and with
the longest follow-up period [14, 16]. The long follow-up period
enabled the estimation of both PFS and OS after salvage PRRT.
Current literature on salvage therapy includes studies with the
Table 5 PFS, OS and median follow-up time in patients receiving I-PRRT, R-PRRT and RR-PRRT with [177Lu-DOTA,Tyr3]octreotate and in the
control group
I-PRRT/R-PRRT RR-PRRT Control group p
value
Number (%) of
patients
Median (95% CI) Number (%) of
patients
Median (95%
CI)
Number (%) of
patients
Median (95%
CI)
I-PRRT R-PRRT
Follow-up
(months)a
88.6
(79.0–98.2)
30.4 (22.5–38.4) 34.5 (16.5–52.5) 120.2
(90.9–149.5)
PFS (months)a
All tumours 168 (100) 35.4
(33.0–37.8)
14.6 (12.4–16.9) 13 (100) 14.2 (9.8–18.5) 99 (100) 35.5
(30.3–40.7)
0.86b
Foregut
NET
5 (3.0) 51.6
(44.0–59.3)
14.6 (N/A) 1 (7.7) 13.8 (N/A)
Midgut
NET
54 (32.1) 40.8
(31.1–50.5)
14.7 (8.9–20.4) 2 (15.4) 4.7 (N/A) 63 (63.3) 35.5
(31.4–39.7)
0.41b
Hindgut
NET
12 (7.1) 29.4
(11.2–47.6)
20.0 (0.6–39.4) 1 (7.7) 13.5 (N/A)
Pancreatic
NET
53 (31.5) 32.7
(27.2–38.1)
14.4 (11.5–17.2) 4 (30.8) 19.3 (10.4–28.1) 20 (20.2) 39.1
(31.8–46.5)
0.59b
Bronchial
NET
13 (7.7) 25.4
(18.9–31.9)
8.0 (4.5–11.6) 2 (15.4) 12.0 (N/A)
Unknown
NET
31 (18.8) 36.2
(28.2–44.3)
13.6 (9.6–17.6) 3 (23.1) 17.6 (1.4–33.8)
OS (months)a
All tumours 168 (100) 80.8c
(66.0–95.6)
26.2 (17.9–34.5) 13 (100) 39.5 (14.4–64.6) 99 (100) 51.4d
(46.7–56.2)
<0.01e
Foregut
NET
5 (3.0) 81.3
(56.9–105.7)
33.9 (N/A) 1 (7.7) 18.3 (N/A)
Midgut
NET
54 (32.1) 77.3
(55.0–99.5)
23.1 (18.4–27.9) 2 (15.4) 29.6 (N/A) 63 (63.6) 51.0
(44.6–57.4)
<0.01e
Hindgut
NET
12 (7.1) 97.8
(31.8–163.4)
56.9 (8.1–105.6) 1 (7.7) 17.1 (N/A)
Pancreatic
NET
53 (31.5) 93.9
(39.4–148.3)
36.8 (20.8–52.8) 4 (30.8) 44.7 (36.4–53.1) 20 (20.2) 61.5
(49.9–73.2)
0.57e
Bronchial
NET
13 (7.7) 74.7
(22.6–126.8)
26.2 (0.0–52.5) 2 (15.4) 17.8 (N/A)
Unknown
NET
31 (18.8) 77.7
(43.3–112.2)
22.2 (12.7–31.7) 3 (23.1) 20.8 (13.5–28.1)
aMedian follow-up time, PFS and OS were calculated from the date of the first administration of I-PRRT, R-PRRT and RR-PRRT
bControl group vs. I-PRRT (excluding additional PFS due to R-PRRT or RR-PRRT)
c Total OS for I-PRRT, R-PRRT, RR-PRRT and unknown consecutive therapies combined
d Total OS for I-PRRT and unknown consecutive therapies
e Control group vs. I-PRRT, R-PRRT and RR-PRRT combined
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same, other or combinations of radiolabelled somatostatin ana-
logues: [177Lu-DOTA,Tyr3]octreotide after [90Y-
DOTA,Tyr3]octreotide in 27 patients [12]; only [177Lu-
DOTA,Tyr3]octreotate in 33 patients [16], in 33 patients [14]
Fig. 3 PFS and OS in patients with bronchial NET and GEP-NET,
midgut NET and pancreatic NET and in patients in the respective
control groups. The PFS of the R-PRRT group, for comparison with the
PFS in the control group, was obtained after I-PRRT, and thus does not
include the additional PFS due to R-PRRTor RR-PRRT. The two groups
had comparable PFS. The OS of the control group was obtained after I-
PRRT plus unknown other treatment(s) and is compared with the cumu-
lativeOS in patients receiving I-PRRT, R-PRRT, RR-PRRTand unknown
other treatment(s) obtained after the last salvage PRRT
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and in 14 patients [17]; a mixture of [90Y-DOTA,Tyr3]octreotate,
[ 1 7 7Lu-DOTA,Tyr 3 ]oc t r eo t a t e , and [ 1 7 7Lu / 9 0Y-
DOTA,Tyr3]octreotate in 16 patients [13]; and [177Lu-
DOTA,Tyr3]octreotate after [90Y- DOTA,Tyr3]octreotide in 26
patients [15]. Safety profiles of PRRT with 177Lu-labelled and
90Y-labelled somatostatin analogues differ, and in particular renal
toxicity is more often reported after the use of 90Y-labelled com-
pounds [11, 19]. In this study, we focused only on the results of
[177Lu-DOTA,Tyr3]octreotate-based I-PRRT and R-PRRT.
Sabet et al. retrospectively analysed 33 patients (including
14 with advanced pancreatic NET and 6 with advanced mid-
gut NET) withWHO grade I/II metastatic GEP-NET retreated
with [177Lu-DOTA,Tyr3]octreotate after initial [177Lu-
DOTA,Tyr3]octreotate therapy [14]. The cumulative mean
dose of [177Lu-DOTA,Tyr3]octreotate after R-PRRT was
44.3 GBq (range 30–83.7 GBq). The median follow-up times
were 37 and 23 months from the start of I-PRRTand R-PRRT,
respectively. Analysis in relation to tumour type was not re-
ported. Tumour responses according to Southwest Oncology
Group criteria after salvage included 7 patients (21.2%) with
ORR, 15 (45,4%) with SD, and 11 (33.3%) with PD, with a
mean PFS of 13 months (data on OS were not reported).
Reversible grade III/IV haematotoxicity was recorded in 7
patients (21.2%), without any MDS or grade III/IV renal tox-
icity [14]. Yordanova et al. from the same institution recently
reported the results in 15 patients with advanced GEP-NET
retreated with [177Lu-DOTA,Tyr3]octreotate. The highest ad-
ministered dose of [177Lu-DOTA,Tyr3]octreotate (96.6 GBq)
led to bone marrow and kidney absorbed radiation doses of
6.8 and 87 Gy, respectively, but without inducing any grade
III/IV toxicity in these organs, after a median follow-up of
62 months (range 31–134 months) [17].
The 33 patients in our earlier salvage study reported in
2010 [16] were also included in this expanded study, which
led to a doubling of themedian follow-up time to 88.6months.
The original reported time-to-progression following the first
cycle of retreatment with [177Lu-DOTA,Tyr3]octreotate was
17 months, which was based only on patients with ORR and
SD, thereby excluding those with PD.
In the present study, additional cycles of [177Lu-
DOTA,Tyr3]octreotate were well tolerated in the majority of
patients. R-PRRT had to be stopped as a precaution in only four
patients because of persistent myelosuppression. In two of these
patients the maximum cumulative administered dose for I-
PRRT was not reached. One of these four patients developed
MDS, which was diagnosed 1.7 months after the first (and
only) administration of R-PRRT. In our view, 1.7 months is
too short as latency period after the start of retreatment for the
R-PRRT to have been the cause of the MDS. Additionally,
blood transfusion because of grade III haemoglobin toxicity
Table 7 PRRT-related
myeloproliferative toxicities in
the control and retreatment
groups
Control group (n = 230) Retreatment group (n = 181) p value
Any 8 (3.5%) 4 (2.2%) 0.56
AML 2 2
MDS 6 2
Time to diagnosis (months), median (95% CI)
From start of I-PRRT 28.7 (26.9–30.5) 33.8 (16.8–50.9) 0.14
From start of R-PRRT – 11.5 (1.8–21.2)
AML acute myeloid leukaemia, MDS myelodysplastic syndrome
Table 6 PRRT-related subacute haematological toxicities in the control and retreatment groups
Toxicitya Control group
(n = 230)
I-PRRT (n = 181) R-PRRT (n = 181) RR-PRRT (n = 13) p value
Grade III Grade IV Grade III Grade IV Grade III Grade IV Grade III Grade IV Control vs. I-PRRT I-PRRT vs.
R-PRRT
Any 30
(13.0%)
6b
(2.6%)
19
(10.5%)
1
(0.6%)
12
(6.6%)
1
(0.6%)
1
(7.7%)
0
(0.0%)
0.45 (grade III toxicities);
0.14 (grade IV toxicities)
0.26
Haemoglobin 13 0 2 1 1 1 1 0 1.00
Leucocytes 16 1 14 0 6 0 0 0
Platelets 14 5 6 0 5 0 0 0
Creatinine 1 0 0 0 0 0 0 0
aGraded according CTCAE 3.0 during complete follow-up
b Five patients had concurrent grade III toxicities
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was needed before R-PRRT. We therefore hypothesize that
I-PRRT was already and mainly releated to the development
of MDS. However, no factor is known to be able to predict
which patient is prone to the development of such a serious
bone marrow complication [20]. Three of the four patients af-
fected by MDS and AML had no dose-modifying toxicities
during I-PRRT or R-PRRT. None of these four patients had
been pretreated with chemotherapy. There was no indication
of increased renal or haematological toxicity after administra-
tion of cumulative doses of [177Lu-DOTA,Tyr3]octreotate
higher than those administered during I-PRRT.
Of the patients in the retreatment group, 56.0% showed an
ORR of and 43.5% SD after I-PRRT (those with PD after
I-PRRTwere not candidates for R-PRRT and were excluded).
In this respect, an objective best response rate of 15.5% with
an ORR and 59.5%with SD following R-PRRTseems on first
sight to be a worse response than after I-PRRT. However, the
administered dose of [177Lu-DOTA,Tyr3]octreotate in
R-PRRT was only half of that used in I-PRRT, leading to a
lower radiation dose to the tumours. Also, the more advanced
disease state at the start of R-PRRT might have led to a lower
tumour response rate following [177Lu-DOTA,Tyr3]octreotate
treatment. More extensive disease is associated with shorter
OS [9]. The overall changes in tumour uptake scores, as
assessed on planar OctreoScan® scintigraphy before I-PRRT
and RR-PRRT with [177Lu-DOTA,Tyr3]octreotate, were not
statistically significant, and therefore changes in tumour up-
take seem to be poorly associated with the responses seen after
R-PRRT.
It is not surprising that a lower dose (e.g. retreatment with a
cumulative administered dose of 14.8 GBq [177Lu-
DOTA,Tyr3]octreotate) resulted in a trend towards fewer side
effects than a cumulative administered dose of 29.6 GBq.
Retreatment with 14.8 GBq in two cycles may therefore not be
considered as the maximum tolerated administered activity for
retreatment. The present promising efficacy results of salvage
PRRTwith only two cycles of [177Lu-DOTA,Tyr3]octreotate do
not imply that, a priori, these two salvage cycles should be auto-
matically increased to four cycles for retreatment, as used during
I-PRRT. The DCR of 75.0% after two cycles of R-PRRT is
already very encouraging and RR-PRRT with two cycles after
relapse (PFS of 14.2 months) is likewise effective and safe.
PFS was 14.6 months in the entire group of patients with
bronchial NET or GEP-NET after R-PRRT with [177Lu-
DOTA,Tyr3]octreotate and was 19.4 months when PR and
SD were considered as tumour responses. PFS was
14.7 months in patients with midgut NET and 14.4 months
in patients with pancreatic NET after R-PRRT. The fact that
PFS after I-PRRT and after R-PRRTwere correlated supports
the use of PFS as a patient selection criterion for retreatment. It
should be emphasized that this correlation was found in our
study using a minimum PFS of 18.0 months as the selection
criterion for salvage therapy. Sabet et al. similarly found a
more durable PFS after R-PRRT in patients with a longer
PFS after I-PRRT [14].
Currently, targeted therapies such as everolimus and suni-
tinib are available as alternative options for I-PRRT, R-PRRT
and RR-PRRT, and thus as second-line and third-line thera-
pies. Everolimus is currently approved for the treatment of
advanced, progressive, NETs of the pancreas, gastrointestinal
tract and lung, whereas sunitinib is only approved for the
treatment of advanced progressive pancreatic NETs. In the
RADIANT-4 study patients with progressive, nonfunctional
grade I/II gastrointestinal or lung NETs were treated with
everolimus, and showed a PFS of 11.0 months (95% CI 9.2–
13.3) [21]. In patients with advanced, progressive, low-grade
or intermediate-grade pancreatic NETs PFS was comparable
between those treated with everolimus and those treated with
sunitinib: 11.0 months [5] and 11.4 months [3], respectively.
Since the maximum tolerated administered dose of [177Lu-
DOTA,Tyr3]octreotate has yet not been reached, it may be
argued that these targeted therapies should be reserved for
patients with a relapse-PD after salvage PRRT with [177Lu-
DOTA,Tyr3]octreotate.
The NETTER-1 study introduced a form of salvage thera-
py in which the octreotide LAR dose was increased by a factor
of two or three to 60mg every 4 weeks in patients with midgut
NET, all of whom had PD following previous octreotide LAR
treatment [6]. The median PFS was 8.4 months in the control
arm treated with salvage octreotide LAR therapy, substantially
lower than in the patients with midgut NET in the present
study who received R-PRRT. These findings may be of im-
portance in deciding the sequence in the use of octreotide
LAR, including salvage therapy, and subsequent PRRT with
[177Lu-DOTA,Tyr3]octreotate including salvage therapy.
The OS after salvage PRRTwas compared with the OS in
the control group with bronchial NET or GEP-NET. These
two groups were more or less matched with respect to many
baseline characteristics. Despite the high frequency of poor
prognostic parameters, e.g. the presence of liver and bone
metastases in our salvage PRRT group, we still found a re-
markable OS of more than 80 months after R-PRRT and RR-
PRRT combined . Sa lvage the rapy wi th [17 7Lu-
DOTA,Tyr3]octreotate) resulted in an OS almost 30 months
longer than in the control group. However, the numbers of
patients with midgut NET (63 patients) and pancreatic NET
(20 patients) in the control group were unevenly distributed
compared with the respective retreatment groups. Therefore,
subgroups of patients with midgut NET and pancreatic NET
were formed for both the control and retreatment patient
groups, and these were also separately analysed for tumour
response, PFS and OS. The PFS in the patients with midgut
NET and pancreatic NET in the retreatment subgroups
matched the PFS following I-PRRT in the controls. Patients
with midgut NET showed a significantly longer OS of more
than 21 months after retreatment. However, patients with
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pancreatic NET showed a trend towards a longer OS with a
survival benefit of approximately 32 months, although this
was not significantly different. This might have been related
to the availability of only a small number of patients for this
control group and the availability of various alternative treat-
ment options specifically for patients with pancreatic NET.
PRRT is mostly used in patients with well or moderately
differentiated NET, but PRRT can be effective in selected
patients with poorly differentiated neuroendocrine carcinomas
(NECs). In our series, nine patients with grade III NEC (Ki-67
index 20–30%) underwent R-PRRT. Seven of these nine pa-
tients had a favourable tumour response to I-PRRT (four with
PR and four with SD) and also to R-PRRT (one with PR and
six with SD). It is possible that these patients were selected
because of a relatively indolent (for NEC) disease course.
Thus, R-PRRT seems to be a feasible option in a subgroup
of patients with GEP-NEC, primarily in those with a Ki-67
index below 30%.
We present data from the Rotterdam cohort on the efficacy
and safety of salvage treatment with [177Lu-DOTA,
Tyr3]octreotate in patients with relapse-PD after benefiting from
I-PRRT. This patient group was compared with a
nonrandomized control group with bronchial NET or
GEP-NET, including a similar subgroup analysis of patients
with midgut NET and pancreatic NET. The feasibility of
R-PRRT has previously been reported, but the strengths of
this study lie in the selection of both retreatment patients and
non-randomized control patients with bronchial NETor GEP-
NET and their subgroups of patients with midgut NET and
pancreatic NET, the very substantial follow-up time carried
out in a single institution, the large patient cohort size, and
the use of only [177Lu-DOTA,Tyr3]octreotate. In this study of
salvage therapy with [177Lu-DOTA,Tyr3]octreotate up to an
administered cumulative dose of 60.5 GBq, no personalized
dosimetry was used, but instead treatment dosing relied on the
usual follow-up parameters of bone marrow and renal func-
tion. The safe toxicity profile found with this procedure calls
into question the added value of personalized dosimetry [22].
We underline the necessity for randomized controlled trials
to compare the efficacy and safety of retreatment with [177Lu-
DOTA,Tyr3]octreotate and approved targeted therapies (e.g.
everolimus and sunitinib).
Conclusion
Salvage PRRTwith [177Lu-DOTA,Tyr3]octreotate to a cumula-
tive administered dose of up to 60.5 GBq can be performed
safely and effectively after progression following I-PRRTwith
[177Lu-DOTA,Tyr3]octreotate. The safety is similar to that after
I-PRRT. In particular, the incidence of AML and MDS was not
higher and renal toxicity grade III/IV was not observed.
Salvage therapy resulted in a significantly longer OS in patients
with bronchial NET, GEP-NET or midgut NET than in a
nonrandomized control group. In patients with pancreatic
NET, the OS was not significantly different, but there seemed
to be a trend towards improvement in OS after salvage therapy.
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